AbbVie Inc. vs McDonald's Corporation: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and McDonald's Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating McDonald's Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and McDonald's Corporation is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $26.9B for McDonald's Corporation, while their respective market capitalizations stand at $451.5B and $188.3B. AbbVie Inc. is headquartered in United States and McDonald's Corporation operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

McDonald's Corporation: McDonald's is the world's defining quick-service restaurant system. In FY2025, it reported $26.885 billion of consolidated revenue, $8.563 billion of net income, and 45,356 restaurants. Corporate revenue is much smaller than systemwide sales because franchisees record most restaurant sales, while McDonald's books rent, royalties, fees, and company-operated revenue.

AbbVie Inc. and McDonald's Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and McDonald's Corporation.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

McDonald's Corporation business model: McDonald's makes money from franchise royalties, rent, fees, and company-operated restaurant sales. The most powerful part of the model is that franchisees provide most restaurant-level labor and capital, while McDonald's controls brand standards, menu systems, supplier relationships, site economics, digital platforms, and real estate in many markets.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of McDonald's Corporation.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

McDonald's Corporation competitive advantage: McDonald's advantage comes from global brand recognition, restaurant density, drive-thru scale, franchisee capital, real estate control, supplier systems, operating standards, digital loyalty data, and the ability to run value promotions across a huge system.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and McDonald's Corporation each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

McDonald's Corporation growth strategy: McDonald's growth strategy centers on restaurant expansion, core menu strength, value platforms, chicken growth, digital ordering, MyMcDonald's Rewards, delivery partnerships, drive-thru throughput, restaurant modernization, and franchisee execution under the Accelerating the Arches framework.

A closer look at the financial trajectory of AbbVie Inc. and McDonald's Corporation rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

McDonald's Corporation: McDonald's revenue grew from $25.494 billion in FY2023 to $25.920 billion in FY2024 and $26.885 billion in FY2025. FY2025 net income was $8.563 billion, reflecting the power of a franchise-heavy model where corporate income is less exposed to restaurant-level labor and food costs than a mostly company-operated chain would be.